Company on-track to dose first patient in LEU011 Phase 1/2 AERIAL trial during the fourth quarter of 2023 Lead programme, LEU011 previously awarded an Innovation Passport by MHRA for the treatment of solid tumours expressing NKG2D ligands LONDON, Sept. 21, 2023 /PRNewswire/ — Leucid Bio…